Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

BioTime, Inc. (BTX)

Add BTX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 9/18/2017 8:43:02 AM - Followers: 71 - Board type: Free - Posts Today: 0


BioTime, Inc.  (BTX)





Company Information:

BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502

Phone: 510-521-3390
      Fax: 510-521-3389






BioTime, Inc. (NYSE AMEX: BTX) is a biotechnology company engaged in two areas of biomedical research and product development:

  • Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
  • Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us


The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem ("hES") cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer's and Parkinson's disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:

  • • An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.
  • ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.

See this link for more information:









Dr. Michael West, CEO

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines. 

Dr. West's complete CV and background on his research interests are available online at:





Recent News:








Transfer Agent:

American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038


Investor Relations:

Judith Segall

VP of Administration, Corporate Secretary

Phone:  510.521.3390 ext 301






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock.   Being a moderator isn't a sign of endorsement.


Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:


Cannabis Stocks News
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BTX News: AgeX Therapeutics CEO Michael D. West to Participate in Fireside Chat with J. Craig Venter at the Cell & Gene Therapy CEO Forum 09/21/2017 07:00:00 AM
BTX News: BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum 09/21/2017 07:00:00 AM
BTX News: BioTime to Present at the Cantor Fitzgerald Global Healthcare Conference 09/20/2017 07:00:00 AM
BTX News: BioTime to Present at the Ladenburg Thalmann 2017 Healthcare Conference 09/20/2017 07:00:00 AM
BTX News: BioTime Awarded Grant from the NIH 09/18/2017 07:00:00 AM
#708   $BTX's management has a great ability to find Adi2 09/18/17 08:43:02 AM
#707   $BTX sub, Oncocyte, nearing the commercial launch of Adi2 09/18/17 08:36:27 AM
#706   $BTX Sub Oncocyte recruits Sales Exec as commercialization Adi2 09/05/17 07:32:40 AM
#704   Insiders buy @ 2.8 Adi2 08/21/17 03:45:01 PM
#703   Israel Innovation Authority invests another $2M in $BTX Adi2 08/14/17 07:55:48 AM
#702   Mike West @ 2ndQ conference call: Adi2 08/10/17 08:38:42 AM
#701   2Q2017: "The second quarter of 2017 was very Adi2 08/03/17 08:04:17 AM
#700   BioTime $BTX Subsidiary AgeX gets 10$ funding. 87% Adi2 08/02/17 09:28:38 AM
#699   Some great names on this list of Tutes ahab333 07/27/17 01:05:13 PM
#698   $BTX OpRegen® Briefing links. Adi2 07/26/17 03:43:59 AM
#697   BioTime’s subsidiary Oncocyte makes another successful step toward Adi2 07/24/17 08:55:33 AM
#696   #OpRegen by Biotime $BTX: Adi2 07/19/17 07:25:12 AM
#695   I have been doing that and sold my ahab333 07/18/17 03:57:12 PM
#694   It's the pattern it trades. If you want Adi2 07/18/17 03:24:09 PM
#693   ADi2, do you know why shares of BTX ahab333 07/18/17 02:41:39 PM
#692   $BTX – OpRegen to be introduced to institutional Adi2 07/18/17 07:11:00 AM
#691   $BTX DD links for AST-OPC1 Adi2 07/17/17 09:43:18 AM
#690   News out on 5th patient enrolled and injected ahab333 07/17/17 09:22:00 AM
#689   More data, video, coming from ageX, Biotime, $BTX: Adi2 07/13/17 09:34:32 AM
#688   $BTX news: Asterias, Sub, provides an update about AST-OPC1: Adi2 07/12/17 07:45:53 AM
#687   Thanks for taking the time with your reply. Craig305 07/12/17 05:34:03 AM
#686   The investment Thesis with BioTime is that this Adi2 07/12/17 05:19:59 AM
#685   What is the next catalyst to move SP? Craig305 07/11/17 01:10:28 PM
#684   Here's another form 4 just emailed to me: ahab333 07/05/17 07:44:15 PM
#683   Form 4 today: looks like 20,000 common shares ahab333 07/05/17 07:32:29 PM
#682   Market Trends & What's happening out there, In Adi2 06/26/17 11:31:57 PM
#681   Priceless insight Adi. Much appreciated. I can foresee tjcunn 06/25/17 02:03:04 PM
#680   Switching from alternatives to Revenia is worth a discussion. Adi2 06/25/17 03:31:33 AM
#679   That's actually a very good sign. Means the Adi2 06/24/17 03:19:49 PM
#678   Good question. I'd be interested to hear some Perkin78 06/24/17 10:51:48 AM
#677   Quick article about a regenerative medicine startup that Perkin78 06/24/17 10:38:51 AM
#676   $BTX Investor presentation covering Renevia and AMD Therapy. Adi2 06/24/17 06:17:26 AM
#675   Adi -- Your DD and willingness to share tjcunn 06/23/17 09:51:26 PM
#674   Busy Day. BTX takes out partners (Hadasit HBL) Adi2 06/19/17 08:07:29 AM
#673   Biotime Expands & Advances Ophthalmology Portfolio Adi2 06/19/17 07:17:45 AM
#672   “… there are wolves out there that love Adi2 06/19/17 05:46:38 AM
#671   For the record only, Adi, an unschooled physicist terry hallinan 06/18/17 05:50:27 PM
#670   The Investment Thesis for Biotime $BTX: Adi2 06/18/17 03:00:58 AM
#669   Thanks Adi, I am here for the long ahab333 06/16/17 02:59:27 PM
#668   This is a non profit development corp. Currently, Adi2 06/16/17 02:34:30 PM
#667   What's with all the selling here yesterday and ahab333 06/16/17 02:04:18 PM
#666   Cosmetics, for non medical applications is rarely covered Adi2 06/16/17 12:56:20 AM
#665   I know that BTX is a real long ahab333 06/15/17 01:45:41 PM
#664   Thx Adi for the great summary of the tjcunn 06/15/17 12:52:27 PM
#663   There is some minor trading going on with Adi2 06/15/17 05:25:50 AM
#662   Notes of $BTX Renevia Pivotal Data Conference Call 14.6.2017 Adi2 06/15/17 05:12:56 AM
#661   Thanks. That's good with me too. Lingering down Perkin78 06/14/17 02:17:16 PM
#660   Perkin, 3.00 looks more like stronger support IMO ahab333 06/14/17 01:44:51 PM
#659   Started a long position just now. $3.10 support Perkin78 06/14/17 01:41:18 PM
#658   Renevia is Done. CE mark 2017, marketing starts Adi2 06/14/17 10:50:14 AM